Kyorin Pharmaceutical Sustainability Profile
Kyorin Pharmaceutical Co., Ltd., commonly referred to as Kyorin, is a prominent player in the pharmaceutical industry, headquartered in Tokyo, Japan. Established in 1923, the company has made significant strides in research and development, particularly in the fields of respiratory and infectious diseases, as well as urology. Kyorin is renowned for its innovative products, including prescription medications and over-the-counter solutions, which are distinguished by their efficacy and safety profiles. The company has achieved notable market presence, particularly in Japan and other key regions across Asia. With a commitment to advancing healthcare, Kyorin continues to focus on developing unique therapies that address unmet medical needs, solidifying its position as a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does Kyorin Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kyorin Pharmaceutical's score of 35 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Kyorin Pharmaceutical's reported carbon emissions
In 2023, Kyorin Pharmaceutical reported total carbon emissions of approximately 41,812,000 kg CO2e. This figure includes 12,895,000 kg CO2e from Scope 1 emissions, 12,110,000 kg CO2e from Scope 2 emissions, and 16,807,000 kg CO2e from Scope 3 emissions. Notably, the Scope 3 emissions breakdown reveals significant contributions from purchased goods and services (6,233,000 kg CO2e) and capital goods (5,263,000 kg CO2e). Kyorin Pharmaceutical has set ambitious reduction targets, aiming for a 46% reduction in Scope 1 and 2 CO2 emissions by fiscal 2030 compared to fiscal 2013 levels. This commitment underscores the company's proactive approach to mitigating its carbon footprint and addressing climate change. The company has shown a consistent effort in tracking and reporting its emissions, with a total of 25,005,000 kg CO2e for Scope 1 and 2 emissions in 2022, down from 29,074,000 kg CO2e in 2020. This trend indicates a commitment to reducing emissions over time, aligning with industry standards for climate action. Kyorin Pharmaceutical's climate initiatives reflect a broader industry context where pharmaceutical companies are increasingly held accountable for their environmental impact, with many adopting science-based targets to guide their sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | 00,000,000 |
| Scope 2 | - | - | - | - | - | 00,000,000 |
| Scope 3 | - | - | - | - | - | 00,000,000 |
How Carbon Intensive is Kyorin Pharmaceutical's Industry?
How Carbon Intensive is Kyorin Pharmaceutical's Location?
Kyorin Pharmaceutical's Scope 3 Categories Breakdown
A significant portion of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 40% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 37% of Scope 3 emissions.
Top Scope 3 Categories
Kyorin Pharmaceutical's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Kyorin Pharmaceutical has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
